

# Guillain-Barré Syndrome Associated with COVID-19 Vaccination

## Appendix

**Appendix Table.** Clinical features of GBS associated with COVID-19 vaccination\*

Author name (country)	GBS rate	Age, y	Sex	Vaccine	Vaccination to symptom onset, d	Initial symptoms (dysautonomia)	Albuminocytologic dissociation (CSF protein, mg/dl)	Clinical classification	Electro- diagnosis	Brighton criteria†	Antiganglioside antibody	Treatment (drug dose)	Mechanical ventilation	Outcome (GBS disability scale‡)
Presented case (Taiwan)	1/18,801 (ChAdOx1 nCoV-19)	41	M	ChAdOx1 (1 <sup>st</sup> dose)	7	Paresthesia, facial diplegia (No)	Yes (159.8)	Bilateral facial palsy with paresthesia	Equivocal	NA	NA	IVIg (0.4g/kg/day for 5 days)	No	Survived (1)
Theuriet J, et al (France) (1)	NA	72	M	ChAdOx1 (1 <sup>st</sup> dose)	21	Myalgia, paresthesia, dysarthria, ascending paralysis, facial diplegia (No)	Yes (62.0)	Classic GBS	AIDP	1	Anti-GM3 IgM positive	IVIg (0.4g/kg/day for 5 days)	No	Survived (NA)
Hasan T, et al (UK) (2)	NA	62	F	ChAdOx1 (1 <sup>st</sup> dose)	8	Paresthesia, ascending paralysis (No)	Yes (90.0)	Classic GBS	AIDP	1	NA	IVIg (0.4g/kg/day for 5 days)	Yes	Survived (5)
Allen CM, et al (UK) (3)	4/712,050 (ChAdOx1 nCoV-19)	54	M	ChAdOx1 (1 <sup>st</sup> dose)	12	Paresthesia, facial diplegia (No)	Yes (162.6)	Bilateral facial palsy with paresthesia	Equivocal	NA	Negative	Prednisolone (60mg for 5 days)	No	Survived (NA)
		20	M	ChAdOx1 (1 <sup>st</sup> dose)	22	Paresthesia, facial diplegia (No)	Yes (123.2)	Bilateral facial palsy with paresthesia	Equivocal	NA	Negative	Prednisolone (60mg for 5 days)	No	Survived (NA)
		57	M	ChAdOx1 (1 <sup>st</sup> dose)	15	Back pain, paresthesia, dysarthria, facial diplegia (No)	Yes (247.1)	Bilateral facial palsy with paresthesia	Not done	NA	Negative	IVIg	No	Survived (NA)

Author name (country)	GBS rate	Age, y	Sex	Vaccine	Vaccination to symptom onset, d	Initial symptoms (dysautonomia)	Albuminocytologic dissociation (CSF protein, mg/dl)	Clinical classification	Electro- diagnosis	Brighton criteria†	Antiganglioside antibody	Treatment (drug dose)	Mechanical ventilation	Outcome (GBS disability scale‡)
		55	M	ChAdOx1 (1 <sup>st</sup> dose)	22	Paresthesia, facial diplegia no	Yes (89.0)	Bilateral facial palsy with paresthesia	Not done	NA	Negative	No treatment	No	Survived (NA)
Maramattom BV, et al (India) (4)	7/1,200,000 (ChAdOx1 nCoV-19)	43	F	ChAdOx1 (1 <sup>st</sup> dose)	10	Back pain, quadriparesis, facial diplegia (No)	Yes (85.0)	Classic GBS	AIDP	1	NA	IVIG	Yes	Survived (0)
		67	F	ChAdOx1 (1 <sup>st</sup> dose)	14	Paresthesia, quadriparesis, facial diplegia (No)	Yes (345.0)	Classic GBS	AMSAN	1	Negative	IVIG (NA) Plasmapheresis	Yes	Survived (4)
		53	F	ChAdOx1 (1 <sup>st</sup> dose)	12	Paresthesia, quadriparesis, facial diplegia (No)	Yes (120.0)	Classic GBS	AIDP	1	Negative	IVIG (NA)	Yes	Survived (4)
		68	F	ChAdOx1 (1 <sup>st</sup> dose)	14	Paresthesia, quadriparesis, dysphagia, facial diplegia (No)	Yes (75.0)	Classic GBS	AIDP	2	Negative	IVIG (NA)	Yes	Survived (4)
		70	M	ChAdOx1 (1 <sup>st</sup> dose)	11	Paresthesia, quadriparesis, facial diplegia (No)	NA	Classic GBS	AIDP	2	NA	IVIG (NA)	Yes	Survived (4)
		69	F	ChAdOx1 (1 <sup>st</sup> dose)	12	Paresthesia, quadriparesis, facial diplegia (No)	NA	Classic GBS	AIDP	2	NA	IVIG (NA) Plasmapheresis	No	Survived (4)
		69	F	ChAdOx1 (1 <sup>st</sup> dose)	13	Paresthesia, quadriparesis, facial diplegia (No)	Yes (83.0)	Classic GBS	AIDP	1	NA	IVIG (NA)	Yes	Survived (5)
Ogbebor O, et al (USA) (5)	NA	86	F	BNT162b2 (1 <sup>st</sup> dose)	1	Paraparesis (No)	Yes (162.0)	Paraparetic	Not done	2	NA	IVIG (NA)	No	Survived (3)
Patel SU, et al (UK) (6)	NA	37	M	ChAdOx1 (1 <sup>st</sup> dose)	14	Back pain, paresthesia, ascending paralysis (No)	Yes (177.0)	Classic GBS	Not done	2	NA	IVIG (2g/kg/day for 5 days)	No	Survived (NA)
Márquez Loza AM, et al (USA) (7)	NA	60	F	Ad26.COVS.2.S (1 <sup>st</sup> dose)	10	Back pain, paraparesis, facial diplegia (No)	Yes (140.0)	GBS / MFS overlap variants	AIDP	1	Negative	IVIG (2g/kg/day for 2 days)	No	Survived (NA)

Author name (country)	GBS rate	Age, y	Sex	Vaccine	Vaccination to symptom onset, d	Initial symptoms (dysautonomia)	Albuminocytologic dissociation (CSF protein, mg/dl)	Clinical classification	Electro- diagnosis	Brighton criteria†	Antiganglioside antibody	Treatment (drug dose)	Mechanical ventilation	Outcome (GBS disability scale‡)
Waheed S, et al (USA) (8)	NA	82	F	BNT162b2 (1 <sup>st</sup> dose)	14	Myalgia, paresthesia, paraparesis BP fluctuation	Yes (88.0)	Paraparetic	Not done	2	NA	IVIG (NA)	No	Survived (NA)
Razok A, et al (Qatar) (9)	NA	73	M	BNT162b2 (2 <sup>nd</sup> dose)	16	Paraparesis (No)	Yes (80.0)	Paraparetic	AIDP	1	NA	IVIG (0.4g/kg/day for 5 days)	No	Survived (0)
Nasuelli NA, et al (Italy) (10)	NA	59	M	ChAdOx1 (1 <sup>st</sup> dose)	10	Paresthesia, facial diplegia (No)	Yes (140)	Bilateral facial palsy with paresthesia	AIDP	NA	Negative	IVIG (0.4g/kg/day for 5 days)	No	Survived (NA)
Bonifacio GB, et al (UK) (11)	NA	66	M	ChAdOx1 (1 <sup>st</sup> dose)	7	Back pain, paresthesia, facial diplegia (No)	Yes (199)	Bilateral facial palsy with paresthesia	AIDP	NA	Negative	IVIG (NA)	No	Survived (1)
		43	M	ChAdOx1 (1 <sup>st</sup> dose)	11	Myalgia, paresthesia, facial diplegia Urinary retention	Yes (281)	Bilateral facial palsy with paresthesia	AIDP	NA	Negative	IVIG (NA)	No	Survived (2)
		51	M	ChAdOx1 (1 <sup>st</sup> dose)	7	Myalgia, paresthesia, facial diplegia (No)	Yes (514)	Bilateral facial palsy with paresthesia	AIDP	NA	Anti-GM3 positive, anti-GM4 borderline	No treatment	No	Survived (2)
		71	F	ChAdOx1 (1 <sup>st</sup> dose)	12	Back pain, Paresthesia, facial diplegia (No)	Yes (96)	Bilateral facial palsy with paresthesia	AIDP	NA	Negative	No treatment	No	Survived (2)
		53	M	ChAdOx1 (1 <sup>st</sup> dose)	8	Paresthesia, facial diplegia (No)	Yes (122)	Bilateral facial palsy with paresthesia	Not done	NA	Negative	No treatment	No	Survived (1)
McKean N, et al (Malta) (12)	NA	48	M	ChAdOx1 (1 <sup>st</sup> dose)	10	Back pain, facial diplegia, paresthesia, quadriparesis (No)	Yes (126.4)	Classic GBS	AIDP	1	Negative	IVIG (2g/kg/day for 5 days)	No	Survived (1)
James J, et al (India) (13)	NA	60	M	ChAdOx1 (1 <sup>st</sup> dose)	11	Quadriparesis, paresthesia, facial diplegia (No)	Yes (149)	Classic GBS	AMSAN	1	NA	IVIG (2g/kg/day for 5 days)	No	Survived (3)

Author name (country)	GBS rate	Age, y	Sex	Vaccine	Vaccination to symptom onset, d	Initial symptoms (dysautonomia)	Albuminocytologic dissociation (CSF protein, mg/dl)	Clinical classification	Electro- diagnosis	Brighton criteria†	Antiganglioside antibody	Treatment (drug dose)	Mechanical ventilation	Outcome (GBS disability scale‡)
		66	M	ChAdOx1 (1 <sup>st</sup> dose)	12	Ascending paralysis, paresthesia Urinary retention, BP fluctuation	Yes (84)	Classic GBS	AIDP	1	NA	IVIG (2g/kg/day for 5 days), Methylprednisolone (1000 mg for 3 days)	No	Survived (3)
		54	F	ChAdOx1 (1 <sup>st</sup> dose)	13	Quadriparesis, paresthesia, dysphagia (No)	NA	Classic GBS	AIDP	2	Negative	IVIG (2g/kg/day for 5 days), Methylprednisolone (1000 mg for 3 days)	No	Survived (2)
García- Grimshaw M, et al (Mexico) (14)	7/3,890,250 (BNT162b2)	33	M	BNT162b2 (1 <sup>st</sup> dose)	28	Facial diplegia (No)	Yes (67.1)	Bilateral facial palsy with paresthesia	AIDP	NA	NA	IVIG (NA)	No	Survived (1)
		25	M	BNT162b2 (1 <sup>st</sup> dose)	12	Paresthesia, quadriparesis (No)	Yes (64)	Classic GBS	AIDP	1	NA	IVIG (NA)	No	Survived (3)
		53	F	BNT162b2 (1 <sup>st</sup> dose)	6	Quadriparesis (No)	No (15)	Classic GBS	AMAN	2	NA	IVIG (NA)	Yes	Survived (5)
		72	M	BNT162b2 (1 <sup>st</sup> dose)	4	Quadriparesis (No)	NA	Classic GBS	AMAN	2	NA	IVIG (NA)	No	Survived (4)
		31	M	BNT162b2 (1 <sup>st</sup> dose)	11	Quadriparesis (No)	NA	Classic GBS	AIDP	2	NA	IVIG (NA)	No	Survived (3)
		67	F	BNT162b2 (1 <sup>st</sup> dose)	4	Quadriparesis (No)	No (30)	Classic GBS	AMAN	2	NA	IVIG (NA)	Yes	Expired (6)
		81	F	BNT162b2 (1 <sup>st</sup> dose)	3	Quadriparesis (No)	Yes (414)	Classic GBS	AIDP	1	NA	IVIG (NA)	No	Survived (4)
Trimboli M, et al (Italy) (15)	NA	25	F	BNT162b2 (2 <sup>nd</sup> dose)	5	Paraparesis, paresthesia (No)	No (NA)	Paraparetic	AIDP	2	NA	IVIG (0.4g/kg/day for 5 days)	No	Survived (2)
Tutar NK, et al (Turkey) (16)	NA	76	M	CoronaVac (2 <sup>nd</sup> dose)	5	Myalgia, ascending paralysis (No)	No (NA)	Classic GBS	AMSAN	2	Negative	IVIG (2g/kg/day for 5 days)	No	Survived (2)

Author name (country)	GBS rate	Age, y	Sex	Vaccination	Vaccination to symptom onset, d	Initial symptoms (dysautonomia)	Albuminocytologic dissociation (CSF protein, mg/dl)	Clinical classification	Electro- diagnosis	Brighton criteria†	Antiganglioside antibody	Treatment (drug dose)	Mechanical ventilation	Outcome (GBS disability scale‡)
Scendoni R, et al (Italy) (17)	NA	82	F	BNT162b2 (2 <sup>nd</sup> dose)	15	Ascending paralysis, paresthesia (No)	Yes (570)	Classic GBS	AMSAN	1	Anti-sulfatide IgG and IgM positive, anti- GM2 IgM positive, anti-GM4 IgM positive	IVIg (0.4g/kg/day for 5 days)	No	Survived (4)

\*AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor and sensory axonal neuropathy; BP, blood pressures; CSF, cerebral spinal fluid; GBS, Guillain-Barré Syndrome; IVIG, Intravenous immunoglobulin; MFS, Miller-Fisher Syndrome; NA, not available.

†The Brighton Criteria is a diagnostic tool for GBS, ranging from level 1 (highest level) to level 4 (lowest level) of diagnostic certainty by assessing the patient's clinical presentation, cerebrospinal fluid data and nerve conduction velocity findings.

‡GBS Disability Scale grades the patient's functional disability from 0 (healthy) to 6 (dead).

## References

1. Theuriet J, Richard C, Becker J, Pegat A, Bernard E, Vukusic S. Guillain-Barré syndrome following first injection of ChAdOx1 nCoV-19 vaccine: 159 first report. *Rev Neurol (Paris)*. 2021 Jun 24 [Epub ahead of print].
2. Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. *BMJ Case Rep*. 2021;14:e243629. [PubMed https://doi.org/10.1136/bcr-2021-243629](https://doi.org/10.1136/bcr-2021-243629)
3. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. *Ann Neurol*. 2021;90:315–8. [PubMed https://doi.org/10.1002/ana.26144](https://doi.org/10.1002/ana.26144)
4. Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 vaccine. *Ann Neurol*. 2021;90:312–4. [PubMed https://doi.org/10.1002/ana.26143](https://doi.org/10.1002/ana.26143)

5. Ogbebor O, Seth H, Min Z, Bhanot N. Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: a temporal occurrence, not a causal association. *IDCases*. 2021;24:e01143.  
[PubMed https://doi.org/10.1016/j.idcr.2021.e01143](https://doi.org/10.1016/j.idcr.2021.e01143)
6. Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. *BMJ Case Rep*. 2021;14:e242956. [PubMed https://doi.org/10.1136/bcr-2021-242956](https://doi.org/10.1136/bcr-2021-242956)
7. Márquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. *Neurology*. 2021 Apr 6 [Epub ahead of print].
8. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. *Cureus*. 2021;13:e13426.  
[PubMed](#)
9. Razok A, Shams A, Almeer A, Zahid M. Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. *Ann Med Surg (Lond)*. 2021;67:102540. [PubMed https://doi.org/10.1016/j.amsu.2021.102540](#)
10. Nasuelli NA, De Marchi F, Cecchin M, De Paoli I, Onorato S, Pettinaroli R, et al. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. *Neurol Sci*. 2021 Jul 17 [Epub ahead of print]. [PubMed](#)
11. Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, et al. Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine. *J Neurol Neurosurg Psychiatry*. 2021 Jul 14 [Epub ahead of print]. [PubMed https://doi.org/10.1136/jnnp-2021-327027](https://doi.org/10.1136/jnnp-2021-327027)
12. McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. *BMJ Case Rep*. 2021;14:e244125. [PubMed https://doi.org/10.1136/bcr-2021-244125](https://doi.org/10.1136/bcr-2021-244125)

13. James J, Jose J, Gafoor VA, Smita B, Balaram N. Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: a case series. *Neurol Clin Neurosci*. 2021;9:402–5. [PubMed https://doi.org/10.1111/ncn3.12537](https://doi.org/10.1111/ncn3.12537)
14. García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. *Clin Immunol*. 2021;230:108818. [PubMed https://doi.org/10.1016/j.clim.2021.108818](https://doi.org/10.1016/j.clim.2021.108818)
15. Trimboli M, Zoleo P, Arabia G, Gambardella A. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine. *Neurol Sci*. 2021. [PubMed https://doi.org/10.1007/s10072-021-05523-5](https://doi.org/10.1007/s10072-021-05523-5)
16. Tutar NK, Eyigürbüz T, Yildirim Z, Kale N. A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN. *Idegyogy Sz*. 2021;74:286–8. [PubMed https://doi.org/10.18071/isz.74.0286](https://doi.org/10.18071/isz.74.0286)
17. Scendoni R, Petrelli C, Scalon G, Logullo FO. Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine. *Hum Vaccin Immunother*. 2021 Aug 4 [Epub ahead of print]. [PubMed https://doi.org/10.1080/21645515.2021.1954826](https://doi.org/10.1080/21645515.2021.1954826)